Great results but it’s a shame we aren’t trying to get this approved in dogs. Gives us a bit more confidence to hold but it will mean very little in the overall scheme of things. The same goes for cancer trials in mice. People and regulatory authorities want clinical data in humans but a positive announcement all the same.
Ann: iPPS shows 3-year equivalent durability in OA Canine Study, page-31
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
-0.005(2.38%) |
Mkt cap ! $71.73M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 21.0¢ | 19.5¢ | $323.1K | 1.612M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 324 | 20.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 52928 | 5 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |